BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Costa F, van Klaveren D, James S, Heg D, Räber L, Feres F, Pilgrim T, Hong MK, Kim HS, Colombo A, Steg PG, Zanchin T, Palmerini T, Wallentin L, Bhatt DL, Stone GW, Windecker S, Steyerberg EW, Valgimigli M; PRECISE-DAPT Study Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 2017;389:1025-34. [PMID: 28290994 DOI: 10.1016/S0140-6736(17)30397-5] [Cited by in Crossref: 468] [Cited by in F6Publishing: 79] [Article Influence: 156.0] [Reference Citation Analysis]
Number Citing Articles
1 Li Y, Jing Q, Wang B, Wang X, Li J, Qiao S, Chen S, Angiolillo DJ, Han Y. Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial. Am Heart J 2020;228:1-7. [PMID: 32739652 DOI: 10.1016/j.ahj.2020.07.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Han YL. De-escalation of anti-platelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a narrative review. Chin Med J (Engl) 2019;132:197-210. [PMID: 30614864 DOI: 10.1097/CM9.0000000000000047] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
3 Kao CC, Wu MS, Chuang MT, Lin YC, Huang CY, Chang WC, Chen CW, Chang TH. Investigation of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease. PLoS One 2021;16:e0255645. [PMID: 34347826 DOI: 10.1371/journal.pone.0255645] [Reference Citation Analysis]
4 Natsuaki M, Morimoto T, Yamaji K, Watanabe H, Yoshikawa Y, Shiomi H, Nakagawa Y, Furukawa Y, Kadota K, Ando K, Akasaka T, Hanaoka KI, Kozuma K, Tanabe K, Morino Y, Muramatsu T, Kimura T; CREDO‐Kyoto PCI/CABG Registry Cohort 2, RESET, and NEXT trial investigators. Prediction of Thrombotic and Bleeding Events After Percutaneous Coronary Intervention: CREDO-Kyoto Thrombotic and Bleeding Risk Scores. J Am Heart Assoc 2018;7:e008708. [PMID: 29789335 DOI: 10.1161/JAHA.118.008708] [Cited by in Crossref: 55] [Cited by in F6Publishing: 8] [Article Influence: 18.3] [Reference Citation Analysis]
5 de Veer AJWM, Bennaghmouch N, Dewilde WJM, Ten Berg JM. How cardiologists manage antithrombotic treatment of patients with atrial fibrillation undergoing percutaneous coronary stenting: the WOEST survey 2018. Neth Heart J 2021;29:135-41. [PMID: 33052578 DOI: 10.1007/s12471-020-01500-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Chan Pin Yin D, Azzahhafi J, James S. Risk Assessment Using Risk Scores in Patients with Acute Coronary Syndrome. J Clin Med 2020;9:E3039. [PMID: 32967247 DOI: 10.3390/jcm9093039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
7 Kedhi E, Fabris E, van der Ent M, Buszman P, von Birgelen C, Roolvink V, Zurakowski A, Schotborgh CE, Hoorntje JCA, Eek CH, Cook S, Togni M, Meuwissen M, van Royen N, van Vliet R, Wedel H, Delewi R, Zijlstra F. Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. BMJ 2018;363:k3793. [PMID: 30279197 DOI: 10.1136/bmj.k3793] [Cited by in Crossref: 67] [Cited by in F6Publishing: 42] [Article Influence: 22.3] [Reference Citation Analysis]
8 Gremmel T, Michelson AD, Frelinger AL III, Bhatt DL. Novel aspects of antiplatelet therapy in cardiovascular disease. Res Pract Thromb Haemost 2018;2:439-49. [PMID: 30046748 DOI: 10.1002/rth2.12115] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
9 Giallauria F, Di Lorenzo A, Venturini E, Pacileo M, D'Andrea A, Garofalo U, De Lucia F, Testa C, Cuomo G, Iannuzzo G, Gentile M, Nugara C, Sarullo FM, Marinus N, Hansen D, Vigorito C. Frailty in Acute and Chronic Coronary Syndrome Patients Entering Cardiac Rehabilitation. J Clin Med 2021;10:1696. [PMID: 33920796 DOI: 10.3390/jcm10081696] [Reference Citation Analysis]
10 Mullen L, Meah MN, Elamin A, Aggarwal S, Shahzad A, Shaw M, Hasara J, Rashid M, Fisher M, Ali T, Patel B, Ding WY, Grainger R, Heseltine T, Kirmani BH, Obeidat M, Kasolo Y, Thatchil J, Khand A. Risk of Major Bleeding With Potent Antiplatelet Agents After an Acute Coronary Event: A Comparison of Ticagrelor and Clopidogrel in 5116 Consecutive Patients in Clinical Practice. J Am Heart Assoc 2021;10:e019467. [PMID: 33834845 DOI: 10.1161/JAHA.120.019467] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Qian Y, Xu B, Qian X, Cao L, Cheng Y, Liu X, Bai S, Han Z, Wang J. Incidence and Risk Factors for Antiplatelet Therapy-Related Bleeding Complications Among Elderly Patients After Coronary Stenting: A Multicenter Retrospective Observation. Front Pharmacol 2021;12:661619. [PMID: 34393770 DOI: 10.3389/fphar.2021.661619] [Reference Citation Analysis]
12 Magnani G, Ardissino D, Im K, Budaj A, Storey RF, Steg PG, Bhatt DL, Cohen M, Oude Ophius T, Goudev A, Parkhomenko A, Kamensky G, Angiolillo DJ, López-Sendón J, Johanson P, Braunwald E, Sabatine MS, Bonaca MP. Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. J Am Heart Assoc 2021;10:e017008. [PMID: 33559485 DOI: 10.1161/JAHA.120.017008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Crimi G, Morici N, Ferrario M, Ferri LA, Piatti L, Grosseto D, Cacucci M, Mandurino Mirizzi A, Toso A, Piscione F, De Carlo M, Elia LR, Trimarco B, Bolognese L, Bovenzi FM, De Luca G, Savonitto S, De Servi S. Time Course of Ischemic and Bleeding Burden in Elderly Patients With Acute Coronary Syndromes Randomized to Low-Dose Prasugrel or Clopidogrel. J Am Heart Assoc 2019;8:e010956. [PMID: 30636561 DOI: 10.1161/JAHA.118.010956] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 15.0] [Reference Citation Analysis]
14 Kent DM, van Klaveren D, Paulus JK, D'Agostino R, Goodman S, Hayward R, Ioannidis JPA, Patrick-Lake B, Morton S, Pencina M, Raman G, Ross JS, Selker HP, Varadhan R, Vickers A, Wong JB, Steyerberg EW. The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration. Ann Intern Med 2020;172:W1-W25. [PMID: 31711094 DOI: 10.7326/M18-3668] [Cited by in Crossref: 27] [Cited by in F6Publishing: 6] [Article Influence: 13.5] [Reference Citation Analysis]
15 Spinthakis N, Farag M, Rocca B, Gorog DA. More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions. J Am Heart Assoc 2018;7:e007754. [PMID: 29374045 DOI: 10.1161/JAHA.117.007754] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
16 Ullrich H, Münzel T, Gori T. Coronary Stent Thrombosis- Predictors and Prevention. Dtsch Arztebl Int 2020;117:320-6. [PMID: 32605709 DOI: 10.3238/arztebl.2020.0320] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
17 Rondano E, Bertolazzi M, Galluzzo A, Maltese L, Caccianotti P, Macciò S, Mazza S, Ruocco MVD, Favretto S, Occhetta E, Rametta F. Effectiveness and safety of antithrombotic strategies in elderly patients with acute myocardial infarction. World J Cardiol 2020;12:513-25. [PMID: 33312437 DOI: 10.4330/wjc.v12.i11.513] [Reference Citation Analysis]
18 Lindholm D, Sarno G, Erlinge D, Svennblad B, Hasvold LP, Janzon M, Jernberg T, James SK. Combined association of key risk factors on ischaemic outcomes and bleeding in patients with myocardial infarction. Heart 2019;105:1175-81. [PMID: 31055499 DOI: 10.1136/heartjnl-2018-314590] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Ishihara T, Sotomi Y, Tsujimura T, Iida O, Kobayashi T, Hamanaka Y, Omatsu T, Sakata Y, Higuchi Y, Mano T. Impact of diabetes mellitus on the early-phase arterial healing after drug-eluting stent implantation. Cardiovasc Diabetol 2020;19:203. [PMID: 33267863 DOI: 10.1186/s12933-020-01173-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Jang JY, Shin DH, Kim JS, Hong SJ, Ahn CM, Kim BK, Ko YG, Choi D, Hong MK, Park KW, Gwon HC, Kim HS, Jang Y. Optimal duration of DAPT after second-generation drug-eluting stent in acute coronary syndrome. PLoS One 2018;13:e0207386. [PMID: 30475845 DOI: 10.1371/journal.pone.0207386] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
21 Fontana P, Roffi M, Reny JL. Platelet Function Test Use for Patients with Coronary Artery Disease in the Early 2020s. J Clin Med 2020;9:E194. [PMID: 31936845 DOI: 10.3390/jcm9010194] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
22 Flannery L, Liu R, Elmariah S. Dual Antiplatelet Therapy: How Long Is Long Enough? Curr Treat Options Cardiovasc Med 2019;21:17. [PMID: 30929096 DOI: 10.1007/s11936-019-0721-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Terrier J, Daali Y, Fontana P, Csajka C, Reny JL. Towards Personalized Antithrombotic Treatments: Focus on P2Y12 Inhibitors and Direct Oral Anticoagulants. Clin Pharmacokinet 2019;58:1517-32. [PMID: 31250210 DOI: 10.1007/s40262-019-00792-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
24 Patti G, Cavallari I, Antonucci E, Calabrò P, Cirillo P, Gresele P, Palareti G, Pengo V, Pignatelli P, Ricottini E, Marcucci R. Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome. PLoS One 2017;12:e0186961. [PMID: 29059255 DOI: 10.1371/journal.pone.0186961] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
25 Chichareon P, Modolo R, Kerkmeijer L, Tomaniak M, Kogame N, Takahashi K, Chang CC, Komiyama H, Moccetti T, Talwar S, Colombo A, Maillard L, Barlis P, Wykrzykowska J, Piek JJ, Garg S, Hamm C, Steg PG, Jüni P, Valgimigli M, Windecker S, Onuma Y, Mehran R, Serruys PW. Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial. JAMA Cardiol 2020;5:21-9. [PMID: 31693078 DOI: 10.1001/jamacardio.2019.4296] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 14.0] [Reference Citation Analysis]
26 Cao D, Dangas G, Mehran R. Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction: Bleeding Avoidance First and Foremost. J Am Heart Assoc 2021;10:e019889. [PMID: 33559475 DOI: 10.1161/JAHA.120.019889] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Numasawa Y, Sawano M, Fukuoka R, Ejiri K, Kuno T, Shoji S, Kohsaka S. Antithrombotic Strategy for Patients with Acute Coronary Syndrome: A Perspective from East Asia. J Clin Med 2020;9:E1963. [PMID: 32585929 DOI: 10.3390/jcm9061963] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
28 Vidula MK, McCarthy CP, Butala NM, Kennedy KF, Wasfy JH, Yeh RW, Secemsky EA. Causes and predictors of early readmission after percutaneous coronary intervention among patients discharged on oral anticoagulant therapy. PLoS One 2018;13:e0205457. [PMID: 30379868 DOI: 10.1371/journal.pone.0205457] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Fustolo-Gunnink SF, Fijnvandraat K, van Klaveren D, Stanworth SJ, Curley A, Onland W, Steyerberg EW, de Kort E, d'Haens EJ, Hulzebos CV, Huisman EJ, de Boode WP, Lopriore E, van der Bom JG; PlaNeT2 and MATISSE collaborators. Preterm neonates benefit from low prophylactic platelet transfusion threshold despite varying risk of bleeding or death. Blood 2019;134:2354-60. [PMID: 31697817 DOI: 10.1182/blood.2019000899] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
30 Perl L, Franzé A, D'Ascenzo F, Golomb N, Levi A, Vaknin-Assa H, Greenberg G, Assali A, De Ferrari GM, Kornowski R. Elderly Suffering from ST-Segment Elevation Myocardial Infarction-Results from a Database Analysis from Two Mediterranean Medical Centers. J Clin Med 2021;10:2435. [PMID: 34070865 DOI: 10.3390/jcm10112435] [Reference Citation Analysis]
31 Seoudy H, Thomann M, Frank J, Lutz M, Puehler T, Lutter G, Müller OJ, Frey N, Saad M, Frank D. Procedural outcomes in patients with dual versus single antiplatelet therapy prior to transcatheter aortic valve replacement. Sci Rep 2021;11:15415. [PMID: 34326368 DOI: 10.1038/s41598-021-94599-2] [Reference Citation Analysis]
32 Nakamura M, Kadota K, Takahashi A, Kanda J, Anzai H, Ishii Y, Shibata Y, Yasaka Y, Takamisawa I, Yamaguchi J, Takeda Y, Harada A, Motohashi T, Iijima R, Uemura S, Murakami Y; PENDULUM Registry Investigators*. Relationship Between Platelet Reactivity and Ischemic and Bleeding Events After Percutaneous Coronary Intervention in East Asian Patients: 1-Year Results of the PENDULUM Registry. J Am Heart Assoc 2020;9:e015439. [PMID: 32394794 DOI: 10.1161/JAHA.119.015439] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
33 Ueki Y, Vögeli B, Karagiannis A, Zanchin T, Zanchin C, Rhyner D, Otsuka T, Praz F, Siontis GCM, Moro C, Stortecky S, Billinger M, Valgimigli M, Pilgrim T, Windecker S, Suter T, Räber L. Ischemia and Bleeding in Cancer Patients Undergoing Percutaneous Coronary Intervention. JACC CardioOncol 2019;1:145-55. [PMID: 34396175 DOI: 10.1016/j.jaccao.2019.11.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
34 Reaño JDP, Shiu LAB, Miralles KV, Dimalala MGC, Pestaño NS, Punzalan FER, Tumanan-Mendoza B, Reyes MJT, Castillo RR. A systematic review and meta-analysis on the effectiveness of an invasive strategy compared to a conservative approach in patients > 65 years old with non-ST elevation acute coronary syndrome. PLoS One 2020;15:e0229491. [PMID: 32106261 DOI: 10.1371/journal.pone.0229491] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
35 Halbach M, Baldus S. [Platelet inhibition in patients with coronary, cerebral and peripheral macroangiopathy : What, when and how long?]. Internist (Berl) 2018;59:288-303. [PMID: 29340741 DOI: 10.1007/s00108-017-0362-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Hoogeveen RM, Hanssen NMJ, Brouwer JR, Mosterd A, Tack CJ, Kroon AA, de Borst GJ, Ten Berg J, van Trier T, van Lennep JR, Liem A, Serné E, Visseren FLJ, Cornel JH, Peters RJG, Jukema JW, Stroes ESG; PANORAMA working group. The challenge of choosing in cardiovascular risk management. Neth Heart J 2021. [PMID: 34259995 DOI: 10.1007/s12471-021-01599-y] [Reference Citation Analysis]
37 Gao C, Tomaniak M, Takahashi K, Kawashima H, Wang R, Hara H, Ono M, Montalescot G, Garg S, Haude M, Slagboom T, Vranckx P, Valgimigli M, Windecker S, van Geuns RJ, Hamm C, Steg PG, Onuma Y, Angiolillo DJ, Serruys PW. Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. Cardiovasc Diabetol 2020;19:179. [PMID: 33066794 DOI: 10.1186/s12933-020-01153-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
38 Saito Y, Kobayashi Y. Update on Antithrombotic Therapy after Percutaneous Coronary Intervention.Intern Med. 2020;59:311-321. [PMID: 31588089 DOI: 10.2169/internalmedicine.3685-3719] [Reference Citation Analysis]
39 Kawashima H, Gao C, Takahashi K, Tomaniak M, Ono M, Hara H, Wang R, Chichareon P, Suryapranata H, Walsh S, Cotton J, Koning R, Rensing B, Wykrzykowska J, de Winter RJ, Garg S, Anderson R, Hamm C, Steg PG, Onuma Y, Serruys PW. Comparative Assessment of Predictive Performance of PRECISE-DAPT, CRUSADE, and ACUITY Scores in Risk Stratifying 30-Day Bleeding Events. Thromb Haemost 2020;120:1087-95. [PMID: 32572864 DOI: 10.1055/s-0040-1712449] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
40 Buccheri S, Angiolillo DJ, Capodanno D. Evolving paradigms in antithrombotic therapy for anticoagulated patients undergoing coronary stenting. Ther Adv Cardiovasc Dis 2019;13:1753944719891688. [PMID: 31814532 DOI: 10.1177/1753944719891688] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Sim DS, Jeong MH, Kim HS, Gwon HC, Seung KB, Rha SW, Chae SC, Kim CJ, Cha KS, Park JS, Yoon JH, Chae JK, Joo SJ, Choi DJ, Hur SH, Seong IW, Cho MC, Kim DI, Oh SK, Ahn TH, Hwang JY; KAMIR-NIH registry investigators. Clopidogrel versus Aspirin after Dual Antiplatelet Therapy in Acute Myocardial Infarction Patients Undergoing Drug-Eluting Stenting. Korean Circ J 2020;50:120-9. [PMID: 31845550 DOI: 10.4070/kcj.2019.0166] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
42 Yin SH, Xu P, Wang B, Lu Y, Wu QY, Zhou ML, Wu JR, Cai JJ, Sun X, Yuan H. Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis. BMJ 2019;365:l2222. [PMID: 31253632 DOI: 10.1136/bmj.l2222] [Cited by in Crossref: 41] [Cited by in F6Publishing: 22] [Article Influence: 20.5] [Reference Citation Analysis]
43 Castini D, Persampieri S, Sabatelli L, Erba M, Ferrante G, Valli F, Centola M, Carugo S. Utility of the HAS-BLED score for risk stratification of patients with acute coronary syndrome. Heart Vessels 2019;34:1621-30. [PMID: 30969359 DOI: 10.1007/s00380-019-01405-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
44 Mavrakanas TA, Chatzizisis YS, Gariani K, Kereiakes DJ, Gargiulo G, Helft G, Gilard M, Feres F, Costa RA, Morice MC, Georges JL, Valgimigli M, Bhatt DL, Mauri L, Charytan DM. Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents: A Meta-Analysis. Clin J Am Soc Nephrol 2019;14:810-22. [PMID: 31010936 DOI: 10.2215/CJN.12901018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
45 Long T, Peng L, Li F, Xia K, Jing R, Liu X, Xie Q, Yang T, Zhang C. Correlations of DAPT score and PRECISE-DAPT score with the extent of coronary stenosis in acute coronary syndrome. Medicine (Baltimore) 2018;97:e12531. [PMID: 30278543 DOI: 10.1097/MD.0000000000012531] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 3.7] [Reference Citation Analysis]
46 Herrmann J. Common Vascular Toxicities of Cancer Therapies. Cardiol Clin 2019;37:365-84. [PMID: 31587779 DOI: 10.1016/j.ccl.2019.07.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
47 Choi SY, Kim MH, Lee KM, Ko YG, Yoon CH, Jo MK, Yun SC. Comparison of Performance between ARC-HBR Criteria and PRECISE-DAPT Score in Patients Undergoing Percutaneous Coronary Intervention. J Clin Med 2021;10:2566. [PMID: 34200528 DOI: 10.3390/jcm10122566] [Reference Citation Analysis]
48 Buccheri S, D'Arrigo P, Franchina G, Capodanno D. Risk Stratification in Patients with Coronary Artery Disease: A Practical Walkthrough in the Landscape of Prognostic Risk Models. Interv Cardiol 2018;13:112-20. [PMID: 30443266 DOI: 10.15420/icr.2018.16.2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
49 Darmon A, Ducrocq G, Jasilek A, Feldman L, Sorbets E, Ferrari R, Ford I, Tardif JC, Tendera M, Fox KM, Steg PG. Use of risk scores to identify lower and higher risk subsets among COMPASS-eligible patients with chronic coronary syndromes. Insights from the CLARIFY registry. Clin Cardiol 2021;44:58-65. [PMID: 33274779 DOI: 10.1002/clc.23505] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Lee OH, Kim BK, Hong SJ, Kim S, Ahn CM, Shin DH, Kim JS, Kang TS, Ko YG, Choi D, Hong MK, Jang Y. Determinants and Clinical Outcomes of Extended Dual Antiplatelet Therapy over 3 Years after Drug-Eluting Stent Implantation: A Retrospective Analysis. Yonsei Med J 2020;61:597-605. [PMID: 32608203 DOI: 10.3349/ymj.2020.61.7.597] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Saito Y, Kobayashi Y. Update on Antithrombotic Therapy after Percutaneous Coronary Intervention. Intern Med 2020;59:311-21. [PMID: 31588089 DOI: 10.2169/internalmedicine.3685-19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
52 Natsuaki M, Morimoto T, Watanabe H, Nakagawa Y, Furukawa Y, Kadota K, Akasaka T, Hanaoka KI, Kozuma K, Tanabe K, Morino Y, Muramatsu T, Kimura T; CREDO‐Kyoto PCI/CABG registry cohort‐2, RESET and NEXT trial investigators. Ischemic and Bleeding Risk After Percutaneous Coronary Intervention in Patients With Prior Ischemic and Hemorrhagic Stroke. J Am Heart Assoc 2019;8:e013356. [PMID: 31701821 DOI: 10.1161/JAHA.119.013356] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Ismail N, Jordan KP, Rao S, Kinnaird T, Potts J, Kadam UT, Mamas MA. Incidence and prognostic impact of post discharge bleeding post acute coronary syndrome within an outpatient setting: a systematic review. BMJ Open 2019;9:e023337. [PMID: 30787079 DOI: 10.1136/bmjopen-2018-023337] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
54 Ranasinghe MP, Peter K, McFadyen JD. Thromboembolic and Bleeding Complications in Transcatheter Aortic Valve Implantation: Insights on Mechanisms, Prophylaxis and Therapy. J Clin Med. 2019;8. [PMID: 30823621 DOI: 10.3390/jcm8020280] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
55 Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J 2019;40:2632-53. [PMID: 31116395 DOI: 10.1093/eurheartj/ehz372] [Cited by in Crossref: 128] [Cited by in F6Publishing: 69] [Article Influence: 128.0] [Reference Citation Analysis]
56 Sanchez F, Boasi V, Vercellino M, Tacchi C, Cannarile P, Pingelli N, Perri D, Gomez L, Cattunar S, Mascelli G. Risk definition and outcomes with the application of the PEGASUS-TIMI 54 trial inclusion criteria to a "real world" STEMI population: results from the Italian "CARDIO-STEMI SANREMO" registry. BMC Cardiovasc Disord 2021;21:144. [PMID: 33736607 DOI: 10.1186/s12872-020-01780-y] [Reference Citation Analysis]
57 Chatterjee M, Ehrenberg A, Toska LM, Metz LM, Klier M, Krueger I, Reusswig F, Elvers M. Molecular Drivers of Platelet Activation: Unraveling Novel Targets for Anti-Thrombotic and Anti-Thrombo-Inflammatory Therapy. Int J Mol Sci 2020;21:E7906. [PMID: 33114406 DOI: 10.3390/ijms21217906] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
58 Covic A, Genovesi S, Rossignol P, Kalra PA, Ortiz A, Banach M, Burlacu A. Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations. BMC Med 2018;16:158. [PMID: 30227855 DOI: 10.1186/s12916-018-1145-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
59 Tersalvi G, Biasco L, Cioffi GM, Pedrazzini G. Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective. J Clin Med 2020;9:E2064. [PMID: 32630233 DOI: 10.3390/jcm9072064] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
60 Bae S, Kim Y, Gogas BD, Kim MC, Sim DS, Hong YJ, Kim JH, Ahn Y, Jeong MH. Efficacy and safety of drug-eluting stents in elderly patients: A meta-analysis of randomized trials. Cardiol J 2021;28:223-34. [PMID: 31702046 DOI: 10.5603/CJ.a2019.0109] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 Hromadka M, Motovska Z, Hlinomaz O, Kala P, Tousek F, Jarkovsky J, Beranova M, Jansky P, Svoboda M, Krepelkova I, Rokyta R, Widimsky P, Karpisek M. MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary Angioplasty. J Pers Med 2021;11:508. [PMID: 34199723 DOI: 10.3390/jpm11060508] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Gue YX, Jeong YH, Farag M, Spinthakis N, Gorog DA. Precision Treatment in ACS-Role of Assessing Fibrinolysis. J Clin Med 2021;10:929. [PMID: 33804303 DOI: 10.3390/jcm10050929] [Reference Citation Analysis]
63 Hu H, Nakagawa T, Yamamoto S, Honda T, Okazaki H, Uehara A, Yamamoto M, Miyamoto T, Kochi T, Eguchi M, Murakami T, Shimizu M, Tomita K, Nagahama S, Imai T, Nishihara A, Sasaki N, Ogasawara T, Hori A, Nanri A, Akter S, Kuwahara K, Kashino I, Kabe I, Mizoue T, Sone T, Dohi S; Japan Epidemiology Collaboration on Occupational Health Study Group. Development and validation of risk models to predict the 7-year risk of type 2 diabetes: The Japan Epidemiology Collaboration on Occupational Health Study. J Diabetes Investig. 2018;9:1052-1059. [PMID: 29380553 DOI: 10.1111/jdi.12809] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
64 Chan Pin Yin DRPP, Vos GA, van der Sangen NMR, Walhout R, Tjon Joe Gin RM, Nicastia DM, Langerveld J, Claassens DMF, Gimbel ME, Azzahhafi J, Bor WL, Oirbans T, Dekker J, Vlachojannis GJ, van Bommel RJ, Appelman Y, Henriques JPS, Kikkert WJ, Ten Berg JM. Rationale and Design of the Future Optimal Research and Care Evaluation in Patients with Acute Coronary Syndrome (FORCE-ACS) Registry: Towards "Personalized Medicine" in Daily Clinical Practice. J Clin Med 2020;9:E3173. [PMID: 33007932 DOI: 10.3390/jcm9103173] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
65 Simonsson M, Winell H, Olsson H, Szummer K, Alfredsson J, Hall M, Dondo TB, Gale CP, Jernberg T. Development and Validation of a Novel Risk Score for In-Hospital Major Bleeding in Acute Myocardial Infarction:-The SWEDEHEART Score. J Am Heart Assoc 2019;8:e012157. [PMID: 30803289 DOI: 10.1161/JAHA.119.012157] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
66 Costa F, Valgimigli M. The optimal duration of dual antiplatelet therapy after coronary stent implantation: to go too far is as bad as to fall short. Cardiovasc Diagn Ther 2018;8:630-46. [PMID: 30498687 DOI: 10.21037/cdt.2018.10.01] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
67 Arahata M, Asakura H. Antithrombotic therapies for elderly patients: handling problems originating from their comorbidities. Clin Interv Aging 2018;13:1675-90. [PMID: 30237704 DOI: 10.2147/CIA.S174896] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
68 Kim YH, Her AY, Kim BK, Hong SJ, Ahn CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y. Impact of preprocedural coronary flow grade on duration of dual antiplatelet therapy in acute myocardial infarction. Sci Rep 2021;11:11735. [PMID: 34083627 DOI: 10.1038/s41598-021-91130-5] [Reference Citation Analysis]
69 Cho JY, Lee SY, Yun KH, Kim BK, Hong SJ, Ko JS, Rhee SJ, Oh SK, Shin DH, Ahn CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y. Factors Related to Major Bleeding After Ticagrelor Therapy: Results from the TICO Trial. J Am Heart Assoc 2021;10:e019630. [PMID: 33739127 DOI: 10.1161/JAHA.120.019630] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
70 van der Sangen NMR, Rozemeijer R, Chan Pin Yin DRPP, Valgimigli M, Windecker S, James SK, Buccheri S, Ten Berg JM, Henriques JPS, Voskuil M, Kikkert WJ. Patient-tailored antithrombotic therapy following percutaneous coronary intervention. Eur Heart J 2021;42:1038-46. [PMID: 33515031 DOI: 10.1093/eurheartj/ehaa1097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Burlacu A, Genovesi S, Basile C, Ortiz A, Mitra S, Kirmizis D, Kanbay M, Davenport A, van der Sande F, Covic A; EUDIAL Working Group of ERA-EDTA. Coronary artery disease in dialysis patients: evidence synthesis, controversies and proposed management strategies. J Nephrol 2021;34:39-51. [PMID: 32472526 DOI: 10.1007/s40620-020-00758-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
72 Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation 2019;140:240-61. [PMID: 31116032 DOI: 10.1161/CIRCULATIONAHA.119.040167] [Cited by in Crossref: 162] [Cited by in F6Publishing: 29] [Article Influence: 81.0] [Reference Citation Analysis]
73 Ozaki Y, Katagiri Y, Onuma Y, Amano T, Muramatsu T, Kozuma K, Otsuji S, Ueno T, Shiode N, Kawai K, Tanaka N, Ueda K, Akasaka T, Hanaoka KI, Uemura S, Oda H, Katahira Y, Kadota K, Kyo E, Sato K, Sato T, Shite J, Nakao K, Nishino M, Hikichi Y, Honye J, Matsubara T, Mizuno S, Muramatsu T, Inohara T, Kohsaka S, Michishita I, Yokoi H, Serruys PW, Ikari Y, Nakamura M; Task Force on Primary Percutaneous Coronary Intervention (PCI) of the Japanese Cardiovascular Interventional Therapeutics (CVIT). CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) in 2018. Cardiovasc Interv Ther 2018;33:178-203. [PMID: 29594964 DOI: 10.1007/s12928-018-0516-y] [Cited by in Crossref: 50] [Cited by in F6Publishing: 24] [Article Influence: 16.7] [Reference Citation Analysis]
74 Gulizia MM, Colivicchi F, Abrignani MG, Ambrosetti M, Aspromonte N, Barile G, Caporale R, Casolo G, Chiuini E, Di Lenarda A, Faggiano P, Gabrielli D, Geraci G, La Manna AG, Maggioni AP, Marchese A, Massari FM, Mureddu GF, Musumeci G, Nardi F, Panno AV, Pedretti RFE, Piredda M, Pusineri E, Riccio C, Rossini R, di Uccio FS, Urbinati S, Varbella F, Zito GB, De Luca L; ESC Scientific Document Group ., Faculty for approval of the Consensus Document . Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease. Eur Heart J Suppl 2018;20:F1-F74. [PMID: 29867293 DOI: 10.1093/eurheartj/suy019] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 5.7] [Reference Citation Analysis]
75 Tonet E, Pavasini R, Biscaglia S, Campo G. Frailty in patients admitted to hospital for acute coronary syndrome: when, how and why? J Geriatr Cardiol 2019;16:129-37. [PMID: 30923544 DOI: 10.11909/j.issn.1671-5411.2019.02.005] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
76 Gargiulo G, Valgimigli M. Antithrombotic therapy after transcatheter aortic valve implantation: a new piece of the still unresolved puzzle. J Thorac Dis 2017;9:4260-5. [PMID: 29268486 DOI: 10.21037/jtd.2017.10.28] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
77 Ando T, Nakazato K, Kimishima Y, Kiko T, Shimizu T, Misaka T, Yamada S, Kaneshiro T, Yoshihisa A, Yamaki T, Kunii H, Takeishi Y. The clinical value of the PRECISE-DAPT score in predicting long-term prognosis in patients with acute myocardial infarction. Int J Cardiol Heart Vasc 2020;29:100552. [PMID: 32551359 DOI: 10.1016/j.ijcha.2020.100552] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
78 Kent DM, Steyerberg E, van Klaveren D. Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects. BMJ 2018;363:k4245. [PMID: 30530757 DOI: 10.1136/bmj.k4245] [Cited by in Crossref: 95] [Cited by in F6Publishing: 64] [Article Influence: 31.7] [Reference Citation Analysis]
79 Gelbenegger G, Schoergenhofer C, Jilma B, Gager GM, Dizdarevic AM, Mamas MA, Parapid B, Velagapudi P, Siller-Matula JM. Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis. Clin Pharmacol Ther 2021;110:424-31. [PMID: 33668076 DOI: 10.1002/cpt.2226] [Cited by in F6Publishing: 1] [Reference Citation Analysis]